The EU Court of Justice dismisses the appeals of several manufacturers of medicines and upholds the Commission’s decision regarding a pay-for-delay infringement (Lundbeck)

On 25 March 2021, the Court of Justice of the EU (“CJEU”) dismissed the appeals by Lundbeck and five producers of generic medicines against the General Court’s (GC) judgments that upheld the Commission’s decision and the fines it had imposed in its first pay-for-delay infringement decision in 2013. The CJEU upheld the GC rulings and confirmed that Lundbeck (“the originator”) and the generic companies were potential competitors, finding that the existence of a patent cannot, as such, mean that a generic company is not a potential rival, when it has the firm intention and ability to enter the market and shows readiness to challenge the validity of that patent. In addition, the CJEU confirmed that the agreements in question were a restriction of competition “by object” because it was clear

L'accès à cet article est réservé aux abonnés

Déjà abonné ? Identifiez-vous

L’accès à cet article est réservé aux abonnés.

Lire gratuitement un article

Vous pouvez lire cet article gratuitement en vous inscrivant.

 

Version PDF

Auteurs

  • Herbert Smith Freehills (Brussels)
  • Herbert Smith Freehills (London)
  • Herbert Smith Freehills (Brussels)
  • Herbert Smith Freehills (London)
  • Herbert Smith Freehills (Brussels)

Citation

Kyriakos Fountoukakos, Sebastien Moore, Peter Rowland, Kristien Geeurickx, Agathe Célarié, The EU Court of Justice dismisses the appeals of several manufacturers of medicines and upholds the Commission’s decision regarding a pay-for-delay infringement (Lundbeck), 25 mars 2021, e-Competitions Due Process Research Program, Art. N° 100045

Visites 544

Tous les numéros

  • Latest News issue 
  • Tous les News issues
  • Latest Special issue 
  • Tous les Special issues